Central lab market seen reaching $4.83 billion by 2030

The Business Research Company says the central lab market is expanding on stronger clinical research activity, rising trial complexity and growing demand for standardized data. The market is projected to grow from $3.3 billion in 2025 to $3.58 billion in 2026, with Asia-Pacific expected to be the fastest-growing region.

Why it matters: - Central labs help standardize testing across clinical trial sites, which supports more reliable data and cleaner regulatory submissions. - The market’s growth signals more outsourcing by pharmaceutical and biotech companies as trials become more complex. - Demand is rising for lab services tied to precision medicine, AI analytics and data integrity.

What happened: - The Business Research Company published an analysis of the central lab global market through 2035. - The report estimates the market will rise from $3.3 billion in 2025 to $3.58 billion in 2026. - The report projects the market will reach $4.83 billion by 2030. - The report was released Nov. 10, 2026. - A free sample of the report is available here. - The full report is available here.

The details: - The market’s forecast implies 8.4% annual growth from 2025 to 2026. - The report projects 7.8% CAGR from 2026 to 2030. - Historical growth has been supported by more clinical research, more complex trial protocols, higher demand for standardized lab data, expanding pharma R&D pipelines and better laboratory informatics. - Forecast-period drivers include precision medicine investment, wider use of AI-powered lab analytics, growth in decentralized clinical trials, demand for integrated lab services and stronger regulatory compliance. - Emerging trends include centralized testing models, genetic and biomarker services, digital sample tracking, multi-site trial support and tighter quality control. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to grow the fastest during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report points to a broader shift toward centralized, technology-enabled trial infrastructure. - The growth outlook suggests labs that can combine testing, analytics and compliance support may be best positioned for demand. - Rising clinical trial counts are a direct tailwind for central lab providers. - For example, the Association of the British Pharmaceutical Industry reported in December 2024 that UK clinical trials launched rose from 411 in 2022 to 426 in 2023.

What's next: - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards and hotspot infographics. - The company also plans updated graphics, tables and future trend analysis across its report set. - The Asia-Pacific market bears watching as the fastest-growing regional opportunity.

The bottom line: - Central lab demand is growing as drug development becomes more data-heavy, more regulated and more distributed across sites.